



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010

(THE FIGURES HAVE NOT BEEN AUDITED)

CONDENSED CONSOLIDATED INCOME STATEMENTS FOR THE PERIOD ENDED 30 SEPTEMBER 2010

	Note	3 MONTHS ENDED		PERIOD ENDED	
		30/09/2010	30/09/2009	30/09/2010	30/09/2009
		RM'000	RM'000	RM'000	RM'000
Revenue	9	81,613	72,403	236,264	212,601
Cost of sales		(59,914)	(54,385)	(173,378)	(160,627)
Gross profit		21,699	18,018	62,886	51,974
Other income		176	306	862	888
Selling & marketing expenses		(10,295)	(9,337)	(29,661)	(26,805)
Administrative expenses		(3,606)	(3,060)	(10,487)	(8,952)
Other expenses		(184)	(145)	(337)	(499)
Finance cost		(94)	(134)	(265)	(508)
Share of results of associates		1,396	665	2,769	1,737
Profit before tax	9	9,092	6,313	25,767	17,835
Income tax expense	21	(1,410)	(1,121)	(5,118)	(3,806)
Net profit for the period		7,682	5,192	20,649	14,029
Attributable to:					
Equity holders of the Company		7,222	4,966	19,726	13,411
Minority interest		460	226	923	618
Net profit for the period		7,682	5,192	20,649	14,029

Earnings per share attributable to equity holders of the Company:

		<u>Sen</u>	<u>Sen</u>	<u>Sen</u>	<u>Sen</u>
- Basic	30	7.71	5.30	21.05	14.31
- Diluted	30	7.71	5.30	21.05	14.31

The Condensed Consolidated Income Statements should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the Interim Financial Report.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010

(THE FIGURES HAVE NOT BEEN AUDITED)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 30 SEPTEMBER 2010

	3 MONTHS ENDED		PERIOD ENDED	
	30/09/2010	30/09/2009	30/09/2010	30/09/2009
	RM'000	RM'000	RM'000	RM'000
Net profit for the period	7,682	5,192	20,649	14,029
Other comprehensive income / (expense)				
Currency exchange differences on translating foreign entities	(435)	-	(435)	-
Deferred tax on revaluation reserve	-	-	(33)	-
Total comprehensive income for the period	7,247	5,192	20,181	14,029
Attributable to:				
Equity holders of the Company	6,793	4,966	19,264	13,411
Minority interest	454	226	917	618
Total comprehensive income for the period	7,247	5,192	20,181	14,029

The Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the Interim Financial Report.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010

(THE FIGURES HAVE NOT BEEN AUDITED)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2010

		<u>Audited</u>
	As at	As at
Note	30/09/2010	31/12/2009
	RM'000	RM'000
ASSETS		
Non-Current Assets		
Property, plant and equipment	10	68,446
Investment properties		4,106
Intangible assets		1,301
Investment in associates	2	34,834
Available-for-sale investment	2	3,928
Deferred tax assets		288
		<u>112,903</u>
Current Assets		
Inventories		40,828
Trade and other receivables		79,535
Derivatives	26	33
Deposits, bank and cash balances		24,194
		<u>144,590</u>
TOTAL ASSETS		<u>257,493</u>
LIABILITIES		
Current Liabilities		
Trade and other payables		55,759
Borrowings	25	2,389
Current tax payable		3,037
Dividend payable		3,749
		<u>64,934</u>
Non-Current Liabilities		
Borrowings	25	7,179
Deferred tax liabilities		4,722
		<u>11,901</u>
TOTAL LIABILITIES		<u>76,835</u>
NET ASSETS		<u>180,658</u>
EQUITY		
Equity attributable to equity holders of the Company		
Share capital	7	93,717
Reserves		6,726
Retained earnings		69,383
		<u>169,826</u>
Minority interest		10,832
TOTAL EQUITY		<u>180,658</u>
		<u>RM</u>
Net Assets per share attributable to ordinary equity holders of the Company		<u>1.81</u>
		<u>RM</u>
		<u>2.17</u>

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the Interim Financial Report.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010

(THE FIGURES HAVE NOT BEEN AUDITED)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 30 SEPTEMBER 2010

	Note	<u>Non-Distributable</u>			<u>Distributable</u>		Minority Interests	Total Equity
		Share Capital	Share Premium	Revaluation & other reserves	Retained Profits	Total		
		RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
<u>PERIOD ENDED 30 SEPTEMBER 2010</u>								
Balance as at 1 January 2010		74,974	5,305	7,188	75,081	162,548	9,835	172,383
Net profit for the 9-months period		-	-	-	19,726	19,726	923	20,649
Other comprehensive income/(expense)		-	-	(462)	-	(462)	(6)	(468)
Total comprehensive income/(expense)		-	-	(462)	19,726	19,264	917	20,181
Minority interests in subsidiary		-	-	-	-	-	80	80
Issue of bonus shares	7	18,743	(5,305)	-	(13,438)	-	-	-
Share issue expenses		-	-	-	(84)	(84)	-	(84)
Dividends	8	-	-	-	(11,902)	(11,902)	-	(11,902)
Balance as at 30 September 2010		93,717	-	6,726	69,383	169,826	10,832	180,658
<u>PERIOD ENDED 30 SEPTEMBER 2009</u>								
Balance as at 1 January 2009		74,974	5,305	3,992	58,419	142,690	7,430	150,120
Net profit for the 9-months period		-	-	-	13,411	13,411	618	14,029
Other comprehensive income/(expense)		-	-	-	-	-	-	-
Total comprehensive income/(expense)		-	-	-	13,411	13,411	618	14,029
Dividends	8	-	-	-	(5,482)	(5,482)	-	(5,482)
Balance as at 30 September 2009		74,974	5,305	3,992	66,348	150,619	8,048	158,667

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the Interim Financial Report.

**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010**(THE FIGURES HAVE NOT BEEN AUDITED)****CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE PERIOD ENDED 30 SEPTEMBER 2010**

	PERIOD ENDED	
	30/09/2010	30/09/2009
	RM'000	RM'000
Cash flows from operating activities		
Profit before tax	25,767	17,835
Adjustments:		
Depreciation and amortization	4,616	4,630
Net profit on disposal of property, plant and equipment	(150)	(173)
Share of results of associates	(2,769)	(1,737)
Fair value changes of derivatives	(33)	-
Other non-cash items	681	4,016
Operating profit before working capital changes:	28,112	24,571
Inventories and receivables	(11,347)	(9,403)
Payables	8,423	9,076
Cash generated from operations	25,188	24,244
Tax paid	(3,573)	(2,419)
Net cash generated from operating activities	21,615	21,825
Cash flows from investing activities		
Dividends received from associate	-	501
Minority interests capital contribution	80	-
Purchase of property, plant and equipment & intangible assets	(6,835)	(2,384)
Proceeds from disposal of property, plant and equipment	150	179
Interest received	128	71
Net cash used in investing activities	(6,477)	(1,633)
Cash flows from financing activities:		
Term loans repaid	(2,057)	(2,247)
Dividends paid	(8,153)	(2,530)
Share issue expenses paid	(84)	-
Other financing activities paid	(381)	(4,730)
Net cash used in financing activities	(10,675)	(9,507)
Net increase in cash and cash equivalents	4,463	10,685
Cash and cash equivalents at the beginning of the financial period	19,950	5,711
Currency translation difference	(219)	-
Cash and cash equivalents at the end of the financial period	24,194	16,396

The Condensed Consolidated Statement of Cash Flow should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the Interim Financial Report.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 SEPTEMBER 2010

1 Basis of Preparation and Accounting policies

The interim financial report has been prepared under the historical cost convention except for the following assets and liabilities which are stated at fair values: properties included within property, plant and equipment as disclosed in note 10, investment properties, and derivatives. The Interim Financial Report is unaudited and has been prepared in compliance with FRS No.134, "Interim Financial Reporting" and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad. It should be read in conjunction with the Group's most recent audited financial statements for the year ended 31 December 2009.

The significant accounting policies adopted are consistent with those adopted in the audited financial statements for the year ended 31 December 2009, except for the adoption of the following Financial Reporting Standards ("FRS") and Issues Committee ("IC") Interpretations:

FRS 7: Financial Instruments: Disclosures

FRS 8: Operating Segments

FRS 101: Presentation of Financial Statements (revised)

FRS 123: Borrowing Costs

FRS 139: Financial Instruments: Recognition and Measurement

Amendments to FRS 1: First-time Adoption of Financial Reporting Standards and FRS 127: Consolidated and Separate Financial Statements: Cost of an Investment in a Subsidiary, Jointly Controlled Entity or Associate

Amendments to FRS 132: Financial Instruments: Presentation

Amendments to FRS 139: Financial Instruments: Recognition and Measurement, FRS 7: Financial Instruments: Disclosures and IC Interpretation 9: Reassessment of Embedded Derivatives

Amendments to FRSs 'Improvements to FRSs (2009)'

IC Interpretation 9: Reassessment of Embedded Derivatives

IC Interpretation 10: Interim Financial Reporting and Impairment

IC Interpretation 11: FRS 2 - Group and Treasury Share Transactions

IC Interpretation 13: Customer Loyalty Programmes

IC Interpretation 14: FRS 119 - The Limit on a Defined Benefit Asset, Minimum Funding Requirements and their Interaction

The adoption of the above standards, amendments and interpretations do not have any material impact on the financial statements of the Group except for the adoption of the following standards:

The revised FRS 101 separates owner and non-owner changes in equity. Therefore, the consolidated statement of changes in equity will now include only details of transactions with owners. All non-owner changes in equity are presented as a single line labelled as total comprehensive income. The Standard also introduces the statement of comprehensive income: presenting all items of income and expense recognised in the income statement, together with all other items of recognised income and expense, either in one single statement, or in two linked statements. The Group has elected to show all items of income and expense in two linked statements. In addition, a statement of financial position is required at the beginning of the earliest comparative period following a change in accounting policy, the correction of an error or the reclassification of items in the financial statements. This revised FRS does not have any impact on the financial position and results of the Group.

The adoption of FRS 139 has resulted in the recognition of short term forward forex contracts at fair values classified as derivatives upon initial adoption. Subsequent changes to the fair values of the derivatives are recognized as other income or expense in the income statement.

2 Reclassification

On 15 March 2010, the Group's Investment in Associate, Maritzberg Investments Ltd., which holds 95% equity interest in PT Penta Valent ("PT PV") has been reclassified as available-for-sale financial asset following the resignation of the Group's sole corporate representative from the PT PV Board of Commissioners.

3 Audit report qualifications of the preceding annual financial statements

The Auditors had reported without any qualifications on the Group's audited financial statements for the year ended 31 December 2009.

4 Seasonality or cyclicity of interim operations

The Group's interim operations are not affected materially by any seasonal or cyclical factors.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 SEPTEMBER 2010 (continued)

5 Unusual items

There were no unusual items that affected the assets, liabilities, equity, net income or cash flows for the period ended 30 September 2010.

6 Changes in estimates of amounts reported in prior interim periods of the current financial year or in prior financial year

There were no changes in estimates of amounts reported in the prior interim periods of the current financial year or prior financial year.

7 Issuances, cancellations, repurchases, resale and repayments of debt and equity securities

As reported in the previous quarter, the Company increased its issued and paid up share capital from RM 74,973,500 to RM 93,716,875 by way of issuance of 18,743,375 new ordinary shares of RM 1.00 each credited as fully paid on the basis of one (1) bonus share for every four (4) existing ordinary shares of RM 1.00 each in the Company ("bonus issue") on 21st June 2010.

Other than the above, there were no issuance and/or repayment of debt and equity securities, share buy-backs, share cancellations, shares held as treasury shares and resale of treasury shares during the period ended 30 September 2010.

8 Dividends paid

The amount of dividends paid/payable during the current and previous interim periods are as follows:

	30/09/2010	30/09/2009
	RM'000	RM'000
In respect of the financial year ended 31 December		
2010: Interim Tax-exempt Dividend of 4 sen per share payable on 15-Oct-10	3,749	-
2009: Final Dividend of 4.5 sen gross per share less tax and Special Dividend of 10.0 sen gross per share less tax paid on 23-Jun-10	8,153	-
2009: Interim Dividend of 5.25 sen per share less tax paid on 16-Oct-09	-	2,952
2008: Final Dividend of 4.5 sen gross per share less tax paid on 23-Jun-09	-	2,530
	<u>11,902</u>	<u>5,482</u>

9 Segment Information

The Group concluded that the reportable operating segments determined in accordance with FRS 8 are materially the same as the business segments previously identified under FRS 114 based on information that internally is provided to the Chief Executive Officer, who is the Group's chief operating decision maker.

OPERATING SEGMENTS	Manufacturing	Wholesale, marketing and distribution	Investment holding	GROUP
PERIOD ENDED 30/09/2010	RM'000	RM'000	RM'000	RM'000
Total Revenue	56,627	194,237	11,814	262,678
Inter-segment revenue	(15,810)	-	(10,604)	(26,414)
External Revenue	40,817	194,237	1,210	236,264
Segment Results (external)	16,006	9,981	(1,271)	24,716
Unallocated corporate expenses				(1,453)
Finance costs				(265)
Share of results of associate				2,769
Profit before tax				25,767
PERIOD ENDED 30/09/2009	RM'000	RM'000	RM'000	RM'000
Total Revenue	50,339	176,174	9,055	235,568
Inter-segment revenue	(14,357)	-	(8,610)	(22,967)
External Revenue	35,982	176,174	445	212,601
Segment Results (external)	12,547	6,498	(1,580)	17,465
Unallocated corporate expenses				(859)
Finance costs				(508)
Share of results of associate				1,737
Profit before tax				17,835
Segment assets				
30-Sep-2010	81,814	123,990	51,185	256,989
31-Dec-2009	71,518	119,012	46,067	236,597



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 SEPTEMBER 2010 (continued)

10 Valuations of Property, Plant and Equipment

The carrying value of land and buildings is based on a valuation carried out in the year ended 31 December 2009 by independent qualified valuers using the comparison and depreciated replacement cost methods to reflect their market value.

11 Significant Post Balance Sheet Events

There were no significant events that had arisen subsequent to the end of this current period.

12 Changes in Group Composition

As reported in the previous quarter, the Company has acquired on 28th July 2010 the entire share capital of Apex Retail Sdn Bhd ("ARSB") to house its retail pharmacy business. ARSB in turn subscribed for 120,000 ordinary shares at RM 1 per share representing 60% equity in the share capital of CS Health Store Sdn Bhd ("CSHS") on 9th August 2010. CSHS was established as a joint venture to operate a retail pharmacy at City Square Mall, Johor Bahru.

Other than the above, the Group did not undertake any business combinations, acquisitions or disposals of subsidiaries and long-term investments, restructuring or discontinuation of operations during the period ended 30 September 2010.

13 Changes in Contingent liabilities or Contingent assets.

There were no contingent liabilities or contingent assets of the Group since the end of the last annual balance sheet date.

14 Capital Commitments

Capital commitments of property, plant and equipment not provided for in the financial statements as at 30 September 2010 are as follows:

	RM'000
Authorised capital expenditure approved and contracted for	494
Authorised capital expenditure approved but not contracted for	2,193
	<u>2,687</u>

15 Related Party Transactions

There were no related party transactions during the period ended 30 September 2010.

16 Review of Performance

For the third quarter of 2010, the Group achieved pretax profits of RM 9.1 million on revenue of RM 81.6 million, increases of 44% and 12.7% respectively of that achieved in the similar period last year. Year to date, the Group recorded pretax profits of RM 25.7 million and revenue of RM 236 million, representing year-on-year growth of 44.5% and 11.1% respectively.

Year to date, its manufacturing division, XepaSP revenue grew 12% over the previous year, with sales to all market sectors exceeding budget expectations. Its market-leading range of cough and cold syrups was further strengthened with the launch of Sedilix Rx and Cough-en Rx formulations.

Wholesale and Distribution continued to show steady revenue growth on improved margins, helped by strong contributions from its Consumer and Pharma divisions. Revenue from the Group's house brands of AVEX and AGNESIA, recorded growth of 25% and 14% respectively over the same period last year, due to intensified marketing efforts and export sales.

Contribution from associated company Xiamen Maidiken Science & Technology Co Ltd is RM 2.7 million for the 9 months of year 2010, a growth of 59.4% over year 2009, supported by strong contributions from its distribution and retail operations in Fujian Province.

17 Material changes in the profit before tax for the quarter

Profit before tax for the current quarter is RM 9.1 million compared to RM 7.82 million in the previous quarter. The 16.1% increase in profit before tax is attributed largely to increased revenue across all business units within the Group and a growing proportion of higher margin house brands in the sales mix.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 SEPTEMBER 2010 (continued)

18 Commentary

(a) Prospects

The Group's performance is the result of careful strategic business planning and meticulous attention to the management of gross margins, operating costs, receivables and inventories in all business units. Barring unforeseen circumstances, the Board expects the Group's performance in the remaining quarter and for the year to be good.

(b) Progress to achieve forecast revenue or profit estimate

Not applicable.

19 Statement by the Board of Directors' opinion on the achievability of forecast revenue or profit estimate

Not applicable.

20 Profit Forecast /Profit Guarantee

Not applicable.

21 Income Tax Expense

	3 MONTHS ENDED		PERIOD ENDED	
	30/09/2010	30/09/2009	30/09/2010	30/09/2009
	RM'000	RM'000	RM'000	RM'000
In respect of current period:				
income tax	1,527	947	5,044	3,418
deferred tax	120	297	311	510
	1,646	1,244	5,354	3,928
In respect of prior period:				
income tax	(237)	(123)	(237)	(122)
	1,410	1,121	5,118	3,806

The effective tax rate for the current quarter and financial year-to-date was lower than the statutory tax rate principally due to the net of tax profits contributed by the Group's associated company.

22 Sale of Unquoted Investments and/or Properties

There were no sale of unquoted investments and/or properties during the period ended 30 September 2010.

23 Quoted Securities

(a) There were no acquisitions or disposals of quoted securities during the period ended 30 September 2010.

(b) There were no quoted securities held as at 30 September 2010.

24 Status of Corporate Proposals

There were no corporate proposals announced but not completed as at 10th November 2010.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 SEPTEMBER 2010 (continued)

25 Group Borrowings and Debt Securities

	AS AT	
	30/09/2010	31/12/2009
	RM'000	RM'000
Short term bank borrowings		
Secured	122	255
Unsecured	2,267	2,543
Total	2,389	2,798
Long term bank borrowings		
Secured	-	64
Unsecured	7,179	8,879
Total	7,179	8,943
Bank borrowings denominated in foreign currency as at 30 September 2010:	SGD'000	RM'000
Singapore Dollars	52	122

The Group did not have any non-current debt securities denominated in Ringgit Malaysia or foreign currency as at 30 September 2010.

26 Derivatives

(a) The Group's derivatives as at 30 September 2010 are as follows -

Type of Derivatives	Contract / Notional Amount	Changes in Fair Value	
		Assets	Liabilities
		RM'000	RM'000
Currency Forward Foreign Exchange Contracts			
Less than 1 year			
Sale of goods	2,032	20	
Purchase of goods	341	13	
	2,373	33	-

(b) The Group does not anticipate any market or credit risks arising from these derivatives.

(c) The cash requirements relating to these contracts is RM 2,373,000.

(d) There have been no changes since the end of the previous financial year in respect of the following:

- (i) the types of derivative contracts entered into and the rationale for entering into such contracts, as well as the expected benefits accruing from these contracts;
- (ii) the risk management policies in place for mitigating and controlling the risks associated with these derivative contracts; and
- (iii) the related accounting policies.

27 Fair Value Changes of Financial Liabilities

As at 30 September 2010, the Group does not have any financial liabilities measured at fair value through profit or loss.

28 Material Litigations

There is no pending material litigation at the date of this report.

29 Dividends

- (a) The interim tax-exempt dividend of 4 sen per share in respect of the financial period ending 31 December 2010 has been paid on 15th October 2010.
- (b) The total dividend declared and paid to-date in year 2010 is 4 sen per share. (Year 2009: Interim taxable dividend of 5.25 sen gross per share less 25% tax).



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 SEPTEMBER 2010 (continued)

30 Earnings per share

		3 MONTHS ENDED		PERIOD ENDED	
		30/09/2010	30/09/2009	30/09/2010	30/09/2009
			(restated)		(restated)
<u>Basic Earnings per share</u>					
Profit after tax	RM'000	7,222	4,966	19,726	13,411
Weighted average number of ordinary shares in issue	'000	93,717	93,717	93,717	93,717
Basic earnings per share	sen	7.71	5.30	21.05	14.31
<u>Diluted Earnings per share</u>					
Profit after tax	RM'000	7,222	4,966	19,726	13,411
Weighted average number of ordinary shares in issue	'000	93,717	93,717	93,717	93,717
Diluted earnings per share	sen	7.71	5.30	21.05	14.31

The basic and diluted earnings per share for the previous quarter and year-to-date have been restated as result of the adjustment to the weighted average number of ordinary shares in issue which has taken into account the one-for-four bonus issue as if the event had occurred at the beginning of the previous period.